Cormedix Inc. income statement CRMD

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Cormedix Inc. reported revenue of $311.7 million, up 617.0% from the year before. Net income was $163.1 million, a profit margin of 52.3%. Operating income came to $150.1 million, an operating margin of 48.2%. Diluted earnings per share were $2.04. Over the twelve months ended Jun 30, 2026, revenue was $462.2 million and net income was $187.2 million. Across the 9 fiscal years shown, revenue grew from $224,105 in fiscal 2016 to $311.7 million in fiscal 2025, about 147.1% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	462 +280.5%	312 +617.0%	43 +66362.8%	—	0 -65.7%	0 -20.2%	0 -15.5%	0 -34.1%	0 +30.5%	0 +47.0%	0 +6.7%
Cost of revenue	—	22 +628.0%	3 +81153.3%	—	0 -97.5%	0 -27.3%	0 -45.1%	0 -5.9%	0 +245.1%	0 -68.6%	0 +215.0%
Gross profit	383 +229.4%	276 +584.5%	40 +65214.4%	—	0 +46.8%	0 +22.1%	0 +138.2%	-0 -372.5%	0 -84.6%	0 +250.4%	-0 -31.3%
Research and development	28 +241.1%	19 +390.4%	4 -70.0%	13 +23.2%	11 -18.7%	13 -1.8%	13 +21.0%	11 -41.3%	19 -23.1%	24 +55.6%	16 +150.5%
Selling, general and administrative	138 +134.9%	106 +81.1%	59 +63.9%	36 +79.0%	20 +22.4%	16 +17.8%	14 +40.7%	10 +22.2%	8 -6.7%	9 -2.6%	9 -13.5%
Operating expenses	166 +147.7%	126 +100.5%	63	—	31 +4.1%	29 +8.2%	27 +30.3%	21 -22.2%	27 -18.8%	33 +34.6%	25 +48.8%
Operating income	217 +340.1%	150 +771.6%	-22 +54.3%	-49 -59.9%	-31 -4.0%	-29 -8.1%	-27 -29.6%	-21 +21.8%	-27 +18.4%	-33 -33.0%	-25 -48.7%
Foreign currency gain (loss)	—	-0 -67.7%	-0 -6.9%	-0 -178.1%	0 +274.5%	-0 +64.0%	-0 -179.7%	-0 -11719.0%	-0 +98.7%	-0 -68.4%	-0 -21.3%
Other income (expense)	-14	-0 -104.1%	3	—	—	—	—	—	—	—	—
Pretax income	203 +293.6%	150 +876.3%	-19	—	-30 -2.8%	-29 -8.3%	-27 -26.5%	-21 +19.9%	-27 +18.7%	-33 -33.9%	-25 -35.5%
Income tax	16 +3010.2%	-13 -834.7%	-1 -138.2%	—	-1 +53.2%	-1 +75.8%	-5 -2.1%	-5	—	—	—
Net income	187 +265.9%	163 +1009.4%	-18 +61.3%	-46 -56.0%	-30 -5.3%	-28 -28.1%	-22 -34.0%	-16 +38.8%	-27 +18.7%	-33 -33.9%	-25 -35.5%
Basic EPS	30.28 +158.4%	2.25 +850.0%	-0.30 +67.0%	-0.91 -23.0%	-0.74	—	—	—	—	—	—
Diluted EPS	16.93 +106.1%	2.04 +780.0%	-0.30 +67.0%	-0.91 -23.0%	-0.74	—	—	—	—	—	—
Weighted average shares, basic	6 +41.6%	0 +22.4%	0 -99.9%	51 +26.4%	40	—	—	—	—	—	—
Weighted average shares, diluted	11 +77.5%	0 +36.4%	0 -99.9%	51 +26.4%	40	—	—	—	—	—	—
Other measures
Depreciation and amortization	—	1 +339.6%	0 +117.7%	0 -16.4%	0 +36.7%	0 -51.6%	0 +74.6%	0 -1.3%	0 +101.2%	0 +44.1%	0 +69.8%
EBITDA	—	151 +779.3%	-22 +54.6%	-49 -60.1%	-31 -4.0%	-29 -8.4%	-27 -29.4%	-21 +21.9%	-27 +18.5%	-33 -33.0%	-25 -48.7%
Interest coverage	—	53.97x	-621.00x	—	—	—	—	—	—	—	—
Margins
Gross margin	82.78%	88.46%	92.66%	—	94.29%	22.00%	14.37%	-31.76%	7.68%	65.09%	-63.62%
Operating margin	46.95%	48.17%	-51.43%	—	-46,819.91%	-15,417.51%	-11,378.44%	-7,416.31%	-6,250.44%	-9,997.39%	-11,048.80%
Pretax margin	44.00%	48.13%	-44.45%	—	-46,305.23%	-15,429.47%	-11,368.54%	-7,587.87%	-6,242.40%	-10,023.48%	-10,996.46%
Profit margin	40.49%	52.31%	-41.24%	—	-45,409.90%	-14,774.70%	-9,207.70%	-5,801.29%	-6,242.40%	-10,023.45%	-10,996.46%
EBITDA margin	—	48.38%	-51.07%	—	-46,690.54%	-15,385.10%	-11,324.95%	-7,390.44%	-6,233.17%	-9,986.19%	-11,037.38%
Effective tax rate	7.98%	-8.69%	—	—	—	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: CRMD (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Parsippany, NJ
SEC filer status: Non-accelerated filer
SEC CIK: 1410098

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.